Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Says PSE Sales Up Again, Business From Leiner Helps Drive Growth

This article was originally published in The Tan Sheet

Executive Summary

Sales of Perrigo's pseudoephedrine-containing OTC products increased in its latest quarter for the first time since nonprescription PSE drugs were placed behind the counter in October 2006, the private-labeler said Nov. 1

You may also be interested in...

Perrigo Expects To Launch Private Label Prilosec OTC In Early 2008

With a major legal hurdle out of the way, Perrigo expects to launch its "largest opportunity" - the first store brand OTC proton pump inhibitor - by the end of March 2008, the firm said Nov. 1

FDA Panel Narrowly Votes Against Cough/Cold Drugs For Children Up To Age 6

An FDA advisory panel decided in split votes Oct. 19 to recommend immediately that all OTC cough/cold medicines should not be used for 2-to 5-year-old children but are safe for 6- to 12-year-olds

FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status

FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts